Satsuma Pharmaceuticals
Pharmaceuticals, 395 Oyster Pt BLVD, South San Francisco, California, 94080, United States, 1-10 Employees
Phone Number: 65********
Who is SATSUMA PHARMACEUTICALS
We are a clinical-stage biopharmaceutical company dedicated to bringing novel treatments to people who suffer from migraine and other debilitating conditions. Our initial product candidat...
Read More
-
Headquarters: 395 Oyster Pt BLVD, South San Francisco, California, 94080, United States
-
Date Founded: 2016
-
Employees: 1-10
-
Revenue: $5 Million to $10 Million
-
Active Tech Stack: See technologies
Industry: Pharmaceuticals
SIC Code: 2834
|
NAICS Code: 325412 |
Show More
Does something look wrong? Fix it. | View contact records from SATSUMA PHARMACEUTICALS
Satsuma Pharmaceuticals Org Chart and Mapping
Email
Phone
Similar Companies to Satsuma Pharmaceuticals
BridgeBio
-
201-500
-
$ 50 Million to 100 Million
Eiger BioPharmaceuticals
-
11-50
-
$ 10 Million to 25 Million
Sage Therapeutics
-
501-1000
-
$ 1 Million to 5 Million
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding Satsuma Pharmaceuticals
Answer: Satsuma Pharmaceuticals's headquarters are located at 395 Oyster Pt BLVD, South San Francisco, California, 94080, United States
Answer: Satsuma Pharmaceuticals's phone number is 65********
Answer: Satsuma Pharmaceuticals's official website is https://satsumarx.com
Answer: Satsuma Pharmaceuticals's revenue is $5 Million to $10 Million
Answer: Satsuma Pharmaceuticals's SIC: 2834
Answer: Satsuma Pharmaceuticals's NAICS: 325412
Answer: Satsuma Pharmaceuticals has 1-10 employees
Answer: Satsuma Pharmaceuticals is in Pharmaceuticals
Answer: Satsuma Pharmaceuticals top competitors include: BridgeBio , Eiger BioPharmaceuticals , Sage Therapeutics
Answer: Satsuma Pharmaceuticals contact info: Phone number: 65******** Website: https://satsumarx.com
Answer: We are a clinical-stage biopharmaceutical company dedicated to bringing novel treatments to people who suffer from migraine and other debilitating conditions. Our initial product candidate is STS101 (dihydroergotamine (DHE) nasal powder), which we are focused on developing as an important and differentiated therapeutic option for the acute treatment of migraine
Answer:
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface
Get Full Access
Sign in to CIENCE GO Data to uncover contact details
Free credits every month